Read More

Lumos Pharma Announced Oral Presentation Highlighting Data On 15 Subjects From OraGrowtH212 Trial Supportive Of Conclusions From Interim Data Analysis

Lumos Pharma, Inc. (NASDAQ: LUMO) announced today that additional data from its OraGrowtH212 trial was included in an oral presentation of interim results at the 2023 International Meeting of Pediatric Endocrinology (IMPE), held in Buenos Aires, Argentina, March 4-7, 2023.

LUMO

Read More

Amarin Announced New REDUCE-IT Data Showing Benefit Of VASCEPA/VAZKEPA In High-Risk Patients With A Recent Acute Coronary Syndrome Event

Amarin Corporation plc (NASDAQ: AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization).

AMRN